Pacific Biosciences of California, Inc. Derivative Liability, Fair Value, Gross Liability
Pacific Biosciences of California, Inc. (PACB) had Derivative Liability, Fair Value, Gross Liability of $0 as of 2019-12-31, per its 10-K filed 2021-02-26.
Discontinued › Notes
us-gaap:DerivativeFairValueOfDerivativeLiability · last filed 2021-02-26
- 2019-12-31: Derivative Liability, Fair Value, Gross Liability $0.00.
| Period end | Derivative Liability, Fair Value, Gross Liability |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |